Matthias Eder

Prof. Dr. Matthias Eder leads the Division of Radiopharmaceutical Development at the German Cancer Consortium (DKTK) in Freiburg, affiliated with the Department of Nuclear Medicine at the Medical Faculty of Albert-Ludwigs-University Freiburg. His work bridges theranostics, biotechnological innovation, and clinical translation.

• Research Focus: Theranostics (diagnostic-therapeutic duality), bicyclic peptides for tumor targeting, cDNA display for radiopharmaceutical discovery, and clinical validation of novel therapies.
• Key Contributions: Development of PSMA-targeting agents like [²¹¹At]PSAt-3-Ga for α-therapy and [Lu-177]PSMA-617 (Pluvicto^TM) for FDA-approved treatments.
• Clinical Translation: Emphasis on preclinical-to-clinical pipeline for radiopharmaceuticals, leveraging DKTK networks for patient-centric outcomes.
• Team: Collaborates with researchers such as Dr. Ann-Christin Eder, Dr. Mohamed Aymen Omrane, and others in Freiburg.

Publications: Recent works highlight advancements in PSMA-targeted therapies, hybrid imaging molecules, and bicyclic peptide libraries, with a focus on prostate cancer applications. Articles from 2019–2024 demonstrate his group’s commitment to improving radiopharmaceutical stability, binding affinity, and clinical utility.

Partnerships: Integrates expertise from the DKTK Joint Funding-Program and collaborates with clinical partners for therapeutic implementation.